Surfing the MASH Tsunami
Episodes
S3-E44.3 - Anticipating the Aftermath: Previewing Outcomes of Paris NASH
10 Sep 2022
Contributed by Lukas
Send a textThe group concludes the preview of the upcoming Paris NASH conference after taking a thorough look at the diversity of topics in Session 5....
S3-E44.2 - Highlights from Paris NASH and an Integrated Multi-Specialty Approach
10 Sep 2022
Contributed by Lukas
Send a textThis conversation picks up focusing on the program’s opening session: Epidemiology and Public Health. Roger, Louise and Jörn begin to un...
S3-E44.1 - Paris NASH Meeting Preview: Program Highlights on Metabolics
10 Sep 2022
Contributed by Lukas
Send a textIn this conversation, Roger Green, Louise Campbell, Jörn Schattenberg and Rachel Zayas share their particular interests in what’s to com...
S3-E44 - A Preview of Paris NASH and NAFLD Summit 2022
08 Sep 2022
Contributed by Lukas
Send a textThe 8th Paris NASH Meeting takes place on September 8th & 9th, where key opinion leaders from both sides of the Atlantic come together ...
From the Vault: Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs
04 Sep 2022
Contributed by Lukas
Send a textThis conversation from The Vault - Season 3, Episode 25.3 is part of a broader overview of NASH drug development in 2022, led by Stephen Ha...
S3-E43.5 - The Future of Combination Agents in NASH Therapy
04 Sep 2022
Contributed by Lukas
Send a textThe group investigates potential for different combination packages, beginning with Roger’s suggestion for an oral semaglutide. Naim note...
S3-E43.4 - Optimizing Combination Agents
04 Sep 2022
Contributed by Lukas
Send a textThis conversation begins with a broader look at the strategies behind developing combination agents and the role these combination therapie...
S3-E43.3 - Science Partnerships and NASH Trials
03 Sep 2022
Contributed by Lukas
Send a textThe discussion shifts to the challenges behind collaborating in a field that, as Naim puts it, “no one has figured out what to do with.”...
S3-E43.2 - Finding the Right Combinations in NASH Therapy
03 Sep 2022
Contributed by Lukas
Send a textNaim opens this conversation with his hope for finding eventual combination therapies that begin to realize a cure for NASH in some patient...
S3-E43.1 - Combination Agents for Fibrotic Regression
03 Sep 2022
Contributed by Lukas
Send a textThis discussion begins with Naim offering an in-depth look into the mechanics of the recently published combination study. He explains that...
S3-E43 - Combination Agents: a Cornerstone Of Future NASH Therapy?
01 Sep 2022
Contributed by Lukas
Send a textThis episode explores the future of combination agents in NASH Therapy. First author Naim Alkhouri and last author Mazen Noureddin join the...
S3-E42.5 - From the Vault: NASH Patient Care and the Value of Patient Education
28 Aug 2022
Contributed by Lukas
Send a textLouise Campbell convenes liver nursing and nurse educator experts Kathryn Jack, Michele Clayton, Pam O'Donoghue and Patrizia Kunzler t...
S3-E42.4 - Allied Health and Patient Empowerment for NAFLD
28 Aug 2022
Contributed by Lukas
Send a textSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and heal...
S3-E42.3 - Allied Health and Patient Empowerment for NAFLD
27 Aug 2022
Contributed by Lukas
Send a textSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and heal...
S3-E42.2 - Allied Health and Patient Empowerment for NAFLD
27 Aug 2022
Contributed by Lukas
Send a textSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and heal...
S3-E42.1 - Allied Health and Patient Empowerment for NAFLD
27 Aug 2022
Contributed by Lukas
Send a textSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and heal...
S3-E42 — Allied Health and Patient Empowerment for NAFLD
25 Aug 2022
Contributed by Lukas
Send a textSurfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and heal...
S3-E41.6 - From the Vault: Why NASH Drug Trials Fail
21 Aug 2022
Contributed by Lukas
Send a textJörn speaks about co-authoring an article, “The Nonalcoholic Steatohepatitis (NASH) drug development graveyard: established hurdles and ...
S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
21 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
21 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
20 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
20 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
20 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates
18 Aug 2022
Contributed by Lukas
Send a textTHE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NAS...
S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy
14 Aug 2022
Contributed by Lukas
Send a textEpisode 40 focuses on lean NASH, and Michelle Long notes that many patients with lean NASH are diagnosed in the Emergency Department when t...
S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease
14 Aug 2022
Contributed by Lukas
Send a textAs the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients wit...
S3-E40.3 - Importance of Early Diagnosis in Lean NASH
14 Aug 2022
Contributed by Lukas
Send a textAs the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients wit...
S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH
13 Aug 2022
Contributed by Lukas
Send a textAs the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients wit...
S3-E40.1 - Best Practices in Lean NASH: How the Article Came About
13 Aug 2022
Contributed by Lukas
Send a textAs the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients wit...
S3-E40 - Best Practices in Lean NASH -- Authors Provide Back Story
11 Aug 2022
Contributed by Lukas
Send a textAs the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients wit...
S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters
07 Aug 2022
Contributed by Lukas
Send a textThis week's "Conversation from the Vault" comes from September 2021, when Anthony Villiotti of NASH kNOWledge joined Louise ...
S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics
07 Aug 2022
Contributed by Lukas
Send a textOne of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically releva...
S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management
06 Aug 2022
Contributed by Lukas
Send a textOne of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically releva...
S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases
06 Aug 2022
Contributed by Lukas
Send a textOne of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically releva...
S3-E39.1 - Creating An Early Diagnosis NASH Decision Model
06 Aug 2022
Contributed by Lukas
Send a textOne of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically releva...
S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis
04 Aug 2022
Contributed by Lukas
Send a textOne serious challenge in the overall management of Fatty Liver disease involves creating cost-effective methods for "early" diagn...
S3-E38.8 - From the Vault: Discussing Patient empowerment at INCBCN 2022
31 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault concludes with this conversation from the episode discussing the inaugural In...
S3-E38.7 - From the Vault: How Ballooned hepatocyte Reads Affect NASH Clinical Trials
31 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with this conversation from the episode discussing systematic failu...
S3-E38.6 - From the Vault: Patient-Focused Drug Development from Global Liver Institute
31 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with this conversation from the episode reviewing the NASH Patient-...
S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges
30 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with this conversation from the episode announcing the launch of th...
S3-E38.4 - From the Vault: NITs & Advancing NASH Therapy at AASLD 2021
30 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with our second most popular conversation ever, which came from the...
S3-E38.3 - From the Vault: Learning About Stellate Cells and Fibrosis at Paris NASH
30 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with our most popular conversation ever, as Stephen Harrison and Jö...
S3-E38.2 - From the Vault: Scott Friedman on Fibrosis and Precision Medicine
30 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault continues with Scott Friedman's fascinating presentation on precision me...
S3-E38.1 - From the Vault: Why NASH Drug Trials Fail
29 Jul 2022
Contributed by Lukas
Send a textOur week of "Greatest Hits" episodes from the vault starts with Jörn's first featured episode, which we posted in November ...
S3-E38 - SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More!
28 Jul 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami posted on Buzzsprout for the first time on July 23, 2020. Over the past two years, NASH Tsunami has posted 132 epi...
S3-E37.5 - The Need to Focus on NASH Cirrhosis Patients
24 Jul 2022
Contributed by Lukas
Send a texthis week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with c...
S3-E37.4 - The "Pincer Movement" In Cirrhosis Technology: Patient Support vs High-End MedTech
24 Jul 2022
Contributed by Lukas
Send a textThis week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with ...
S3-E37.3 - Where Is The Next Cirrhosis Breakthrough?
23 Jul 2022
Contributed by Lukas
Send a textThis week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with ...
S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?
23 Jul 2022
Contributed by Lukas
Send a textThis week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with ...
S3-E37.1 - Cirrhosis Screening & Diagnostic Tests
23 Jul 2022
Contributed by Lukas
Send a textThis week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with ...
S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?
21 Jul 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami has explored issues of NASH cirrhosis since our earliest episodes in 2020. This episode integrates panelists with ...
S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?
17 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions
17 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid
16 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients
16 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy
16 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?
14 Jul 2022
Contributed by Lukas
Send a textOn July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file ...
S3-E35.5 - Liver Science At #ILC2022: Mid-Range Impact of Advances
10 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday...
S3-E35.4 - Liver Science At #ILC2022: Commercial Benefits From the New Liver Science
10 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday...
S3-E35.3 - Liver Science At #ILC2022: Stellate Cells, Omics and Novel Receptor Targets
09 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday...
S3-E35.2 - Liver Science At #ILC2022: The Interplay of Stellate Cell Dynamics and Hepatic Fibrosis
09 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday...
S3-E35.1 - Liver Science at #ILC2022: Circadian Rhythm and Stellate Cells
09 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday...
S3-E35 - #ILC2022 Look Back: Liver Science and Fibrosis
07 Jul 2022
Contributed by Lukas
Send a textLast month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first m...
S3-E32.3 - #ILC2022 Looking Back: NASH Is a Complex Disease
04 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E32.2 - #ILC2022 Looking Back: NAFLD and Quality-of-Life
04 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E32.1 - #ILC2022 Looking Back: Patient Motivation and Systems Incentives
04 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E34.4 - #ILC2022 looking back: Crystal Balling and The Semaglutide Trial
03 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E33.2 - #ILC2022 Looking Back: Patient Engagement 2 -- Patient Communication
03 Jul 2022
Contributed by Lukas
Send a textDuring last week's #ILC2022 meeting in London, Louise Campbell took the opportunity to sit down with PBC Foundation CEO and Fatty Live...
S3-E33.1 - #ILC2022 Looking Back: Patient Engagement 1 -- Nurses and Touchy Topics
03 Jul 2022
Contributed by Lukas
Send a textDuring last week's #ILC2022 meeting in London, Louise Campbell took the opportunity to sit down with PBC Foundation CEO and Fatty Live...
S3-E34.3 - #ILC2022 Looking Back: Early Pemvidutide Results and a Little More on FIB-4
02 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E34.2 - #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations
02 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E34.1 - #ILC2022 Looking Back: Resmetirom Late-Breaker and Cirrhosis Study
02 Jul 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first ma...
S3-E34 #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!
30 Jun 2022
Contributed by Lukas
Send a textLast week, roughly 5,000 hepatology stakeholders met at the ExCel Centre in London for #ILC2022, the first major hepatology Congress with s...
S3-E33 - Day 4 of ILC2022: Friendly Debates About NITs, PLUS Discussing the Patient Advocate's Perspective
27 Jun 2022
Contributed by Lukas
Send a textThe International Liver Congress (#ILC2022) is the first major hepatology Congress to be held in person since the start of the pandemic (sm...
S3-E32 - Days 1-3 of ILC 2022: The Value of FIB-4 and In-Person Meetings
26 Jun 2022
Contributed by Lukas
Send a textThe International Liver Congress (#ILC2022) is the first major hepatology Congress to be held in person since the start of the pandemic (sm...
S3-E30.4 - Highlighting Intriguing #ILC2022 Abstracts: Potential Uses of FIB-4
19 Jun 2022
Contributed by Lukas
Send a textNext week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress...
S3-E30.3 - Highlighting Intriguing #ILC2022 Abstracts: More on NAFLD Quality of Life
19 Jun 2022
Contributed by Lukas
Send a textNext week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress...
S3-E30.2 - Highlighting Intriguing #ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics
18 Jun 2022
Contributed by Lukas
Send a textNext week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress...
S3-E30.1 - Highlighting Intriguing #ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study
18 Jun 2022
Contributed by Lukas
Send a textNext week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress...
S3-E30 - Previewing #ILC2022: Focus on NITs and Patients
16 Jun 2022
Contributed by Lukas
Send a textThis week, NASH Tsunami identifies some of the most important and intriguing presentations at next week's International Liver Congress...
S3-E29.2 - #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow
12 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E29.1 - #NASHDay 2022 Wrap-up Panel: What #NASHDay Means To Our Community In 2022 and Why It Matters
12 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E28.4 - #NASHDay 2022 Preview: SurfingNASH Predictions
12 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E28.3 - #NASHDay 2022 Preview: Exciting NASH Community Collaboration and How It Drives Us Forward
11 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E28.2 - #NASHDay 2022 Preview: What New Approaches To Clinical Trial Design Will Mean For Our Community
11 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E28.1 - #NASHDay 2022 Preview: New Approaches To Clinical Trial Design
11 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advo...
S3-E29 - #NASHDay 2022: SurfingNASH Wrap-up
10 Jun 2022
Contributed by Lukas
Send a textToday, June 9, was the 5th International NASH Day (#NASHDay). Global Liver Institute (@GlobalLiver), the largest liver patient advocacy org...
S3-E28 - Previewing #NASHDay 2022: Patient Advocacy Thrives!
09 Jun 2022
Contributed by Lukas
Send a textThursday, June 9, marks #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advoc...
S3-E27.6 - 5th Global NASH Congress Wrap-Up: Dual Weight Loss Agonists, Expanded Imaging and the Implications for NAFLD
05 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD-related topics. This...
S3-E27.5 - 5th Global NASH Congress Wrap-Up: NAFLD Screening in Primary Care Practices With The GRIP Program
05 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD-related topics. In t...
S3-E27.4 - 5th Global NASH Congress Wrap-Up: An Interview with Becky Taub
05 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD topics. In this conv...
S3-E27.3 - 5th Global NASH Congress Wrap-Up: Key NAFLD Topics In The Room
04 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD topics. In this conv...
S3-E27.2 - 5th Global NASH Congress Wrap-Up: Quality-of-Life and Portable Liver Scans
04 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of topics related to Fatty Li...
S3-E27.1 - 5th Global NASH Congress Wrap-Up: Fatty Liver Science and Patient Advocacy
04 Jun 2022
Contributed by Lukas
Send a textOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of topics related to Fatty Li...
S3-E27 - 5th Global NASH Congress Wrap-Up: Highlights & Speaker Interviews
02 Jun 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami covered the 5th Global NASH Congress. Louise Campbell and Rachel Zayas conducted speaker interviews with executive...
S3-E26.4 - Advancing NASH Best Practices In NITs: Answering Questions, Next Steps
29 May 2022
Contributed by Lukas
Send a texthis conversation ties up some of the loose ends of the broader "stacking" issue. Quentin Anstee addresses Roger Green's earl...
S3-E26.3 - Advancing NASH Best Practices In NITs: Optimizing a NASH Biomarker Set
29 May 2022
Contributed by Lukas
Send a textThis conversation starts with Roger Green asking Quentin Anstee to clarify exactly what he means by "stacking" variables. Quentin...
S3-E26.2 - Advancing NASH Best Practices In NITs: "Stacking" NASH Biomarkers
28 May 2022
Contributed by Lukas
Send a textThis conversation starts with Quentin Anstee complimenting Stephen Harrison for his observation that when we analyze NASH Biomarkers, we sh...
S3-E26.1 - Advancing NASH Best Practices In NITs: Quentin Anstee's Five Key Takeaways
28 May 2022
Contributed by Lukas
Send a textThis conversation starts with Quentin Anstee sharing the five key takeaways for NITs in general and NIT Best Practices he developed while p...
S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?
26 May 2022
Contributed by Lukas
Send a textQuentin Anstee joins Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green to share recently developed insights about NITs ...